Alpha Tau to Present at Jefferies Global Healthcare Conference
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CFO Raphi Levy will deliver a presentation on June 5, 2025, from 1:25 to 1:55 PM ET in New York. Additionally, Mr. Levy will be available for one-on-one meetings with investors during the conference, which can be scheduled through Jefferies representatives.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore della terapia contro il cancro a radiazione alfa Alpha DaRT®, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il CFO dell'azienda, Raphi Levy, terrà una presentazione il 5 giugno 2025, dalle 13:25 alle 13:55 ET a New York. Inoltre, il signor Levy sarà disponibile per incontri individuali con gli investitori durante la conferenza, che possono essere prenotati tramite i rappresentanti di Jefferies.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la terapia contra el cáncer con radiación alfa Alpha DaRT®, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El CFO de la compañía, Raphi Levy, realizará una presentación el 5 de junio de 2025, de 1:25 a 1:55 PM ET en Nueva York. Además, el Sr. Levy estará disponible para reuniones individuales con inversores durante la conferencia, que pueden programarse a través de los representantes de Jefferies.
Alpha Tau Medical (NASDAQ: DRTS), 알파 방사선 암 치료제 Alpha DaRT®의 개발업체가 다가오는 Jefferies Global Healthcare Conference에 참여할 것이라고 발표했습니다. 회사의 CFO인 Raphi Levy는 2025년 6월 5일 뉴욕에서 동부 표준시 기준 오후 1시 25분부터 1시 55분까지 발표를 진행할 예정입니다. 또한 Levy 씨는 컨퍼런스 기간 동안 투자자들과의 일대일 미팅도 진행하며, 이는 Jefferies 담당자를 통해 예약할 수 있습니다.
Alpha Tau Medical (NASDAQ : DRTS), développeur de la thérapie contre le cancer par rayonnement alpha Alpha DaRT®, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le directeur financier de la société, Raphi Levy, présentera le 5 juin 2025, de 13h25 à 13h55 ET à New York. De plus, M. Levy sera disponible pour des réunions individuelles avec les investisseurs pendant la conférence, qui peuvent être programmées via les représentants de Jefferies.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der Alpha DaRT®-Alpha-Strahlenkrebstherapie, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Der CFO des Unternehmens, Raphi Levy, wird am 5. Juni 2025 von 13:25 bis 13:55 Uhr ET in New York eine Präsentation halten. Darüber hinaus steht Herr Levy während der Konferenz für Einzelgespräche mit Investoren zur Verfügung, die über die Vertreter von Jefferies vereinbart werden können.
- None.
- None.
JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025.
| Event: | Jefferies Global Healthcare Conference |
| Format: | Presentation |
| Date: | June 5, 2025 |
| Time: | 1:25 – 1:55PM ET |
| Location: | New York, NY |
Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
FAQ
When is Alpha Tau Medical (DRTS) presenting at the Jefferies Healthcare Conference 2025?
Who will represent Alpha Tau Medical at the Jefferies Healthcare Conference 2025?
What is Alpha Tau Medical's (DRTS) main product?
Can investors meet with Alpha Tau Medical's management at the Jefferies conference?
